Latest Longevity Products News

Challenger Limited reported a 19% jump in Life sales to $1.7 billion in Q3 FY26, driven by strong annuity demand and offshore growth. Despite a 10% dip in Funds Management FUM amid market volatility, the company advanced key retirement partnerships and tightened its FY26 EPS guidance.

Challenger Limited has welcomed APRA’s new capital framework for longevity products, set to ease capital requirements and reduce risk for providers, supporting Australia’s evolving retirement income market.

Challenger Limited reported a robust 9% rise in normalised net profit after tax to $456 million for FY25, alongside an 11% dividend increase, while welcoming APRA's capital reforms that promise to boost its financial resilience and growth in retirement income products.

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.

Challenger Limited reported a solid 4% increase in total Life sales to $2.5 billion in Q1 FY26, buoyed by strong annuity sales and strategic partnerships. The company reaffirmed its FY26 earnings guidance while highlighting upcoming regulatory changes expected to benefit the sector.